Global Flow Cytometry Market Report to 2031 – Featuring Agilent Technologies, bioMerieux, Bio-Rad Laboratories and Danaher Among Others – Yahoo Finance
Flow Cytometry Market
Dublin, Dec. 06, 2022 (GLOBE NEWSWIRE) — The “Flow Cytometry Market By Component, By Technology, By Application, By End User: Global Opportunity Analysis and Industry Forecast, 2021-2031” report has been added to ResearchAndMarkets.com’s offering.
The flow cytometry market was valued at $4,695.8 million in 2021, and is projected to reach $10,421.6 million by 2031, registering a CAGR of 8.3% from 2022 to 2031.
Report Attribute
Details
No. of Pages
279
Forecast Period
2021 – 2031
Estimated Market Value (USD) in 2021
$4695.8 million
Forecasted Market Value (USD) by 2031
$10421.6 million
Compound Annual Growth Rate
8.3%
Regions Covered
Global
Flow cytometry is a biophysical, laser-based analytical technology that measures and analyzes several physical characteristics of cells or particles suspended in a fluid, when passed through a laser beam. Flow cytometry has various advantages over traditional analytical methods such as ELISA, which has the ability to deliver precise and accurate results and lesser time consumption at approximately the same prices.
Flow cytometry technology is widely used in various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV, and hematological malignancies. Rise in count of patients suffering from HIV and cancer and increase in use of flow cytometry in hospitals & diagnostic centers, which has created an impending need of flow cytometry in effective diagnosis and monitoring of diseases.
Major factors that drive growth of the flow cytometry market include technological advancements and high adoption in various research and diagnostic applications. In addition, advent of flow cytometry technology in novel research applications such as cytogenomics, proteomics, and marine biology further supplement the market growth.
Further, rise in incidences of diseases such as cancer and HIV are expected to boost adoption of flow cytometry technology across diagnostic application. However, factors such as high-cost associated with instruments and reagents, lack of awareness among potential end users, and limited availability of technical expertise are expected to hamper the market growth. Preference of flow cytometry in drug discovery & development and diagnostics is expected to provide numerous growth opportunities.
The flow cytometry market is segmented on the basis of component, technology, application, end user, and region. By component, the flow cytometry market is segmented into instruments, reagents & consumables, software and services. The instrument segment is further divided into platforms, replaceable components, and accessories. The platforms segment is further categorized into sorters and analyzers.
Filters, lasers, detectors, and others are considered as types of replaceable components. The reagents market is further divided into antibodies, dyes, beads, and others. On the basis of technology, the market is segmented into cell-based flow cytometry and bead-based flow cytometry. On the basis of application, it is segmented into academic & clinical applications and diagnostic applications.
The academic & clinical applications segment is further divided into cell cycle analysis & cell proliferation, apoptosis, cell sorting, transfect ion & cell viability, and others. The diagnostic applications segment is further segmented into organ transplantation, hematological malignancies, HIV, solid tumors & cancer, and others. On the basis of end user, the market is categorized into hospitals, medical schools & clinical testing labs, commercial organizations, academic institutions, and others. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits
This report provides a detailed quantitative analysis of the current flow cytometry market trends and forecast estimations from 2022 to 2031, which assists to identify the prevailing market opportunities.
An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
A comprehensive analysis of factors that drive and restrain the growth of the flow cytometry market is provided.
The projections in this report are made by analyzing the current trends and future market potential from 2022 to 2031, in terms of value.
An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which help in understanding competitive outlook of the market.
Key Topics Covered:
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: FLOW CYTOMETRY MARKET, BY COMPONENT
4.1 Overview
4.1.1 Market size and forecast
4.2 Instruments
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Reagents and consumables
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Software
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Services
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
CHAPTER 5: FLOW CYTOMETRY MARKET, BY TECHNOLOGY
5.1 Overview
5.1.1 Market size and forecast
5.2 Cell based flow cytometry
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Bead based flow cytometry
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: FLOW CYTOMETRY MARKET, BY APPLICATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Academic and clinical applications
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Diagnostic applications
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: FLOW CYTOMETRY MARKET, BY END USER
7.1 Overview
7.1.1 Market size and forecast
7.2 Hospitals
7.2.1 Key market trends, growth factors and opportunities
7.2.2 Market size and forecast, by region
7.2.3 Market analysis by country
7.3 Medical schools and clinical testing labs
7.3.1 Key market trends, growth factors and opportunities
7.3.2 Market size and forecast, by region
7.3.3 Market analysis by country
7.4 Commercial organizations
7.4.1 Key market trends, growth factors and opportunities
7.4.2 Market size and forecast, by region
7.4.3 Market analysis by country
7.5 Academic institutions
7.5.1 Key market trends, growth factors and opportunities
7.5.2 Market size and forecast, by region
7.5.3 Market analysis by country
7.6 Others
7.6.1 Key market trends, growth factors and opportunities
7.6.2 Market size and forecast, by region
7.6.3 Market analysis by country
CHAPTER 8: FLOW CYTOMETRY MARKET, BY REGION
CHAPTER 9: COMPANY LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Key developments
CHAPTER 10: COMPANY PROFILES
10.1 Agilent Technologies, Inc.
10.1.1 Company overview
10.1.2 Company snapshot
10.1.3 Operating business segments
10.1.4 Product portfolio
10.1.5 Business performance
10.1.6 Key strategic moves and developments
10.2 Becton Dickinson and Company
10.2.1 Company overview
10.2.2 Company snapshot
10.2.3 Operating business segments
10.2.4 Product portfolio
10.2.5 Business performance
10.2.6 Key strategic moves and developments
10.3 bioMerieux SA
10.3.1 Company overview
10.3.2 Company snapshot
10.3.3 Operating business segments
10.3.4 Product portfolio
10.3.5 Business performance
10.3.6 Key strategic moves and developments
10.4 Bio-Rad Laboratories, Inc.
10.4.1 Company overview
10.4.2 Company snapshot
10.4.3 Operating business segments
10.4.4 Product portfolio
10.4.5 Business performance
10.4.6 Key strategic moves and developments
10.5 Danaher Corporation
10.5.1 Company overview
10.5.2 Company snapshot
10.5.3 Operating business segments
10.5.4 Product portfolio
10.5.5 Business performance
10.5.6 Key strategic moves and developments
10.6 DiaSorin S.p.A.
10.6.1 Company overview
10.6.2 Company snapshot
10.6.3 Operating business segments
10.6.4 Product portfolio
10.6.5 Business performance
10.6.6 Key strategic moves and developments
10.7 Miltenyi Biotec, Inc.
10.7.1 Company overview
10.7.2 Company snapshot
10.7.3 Operating business segments
10.7.4 Product portfolio
10.7.5 Business performance
10.7.6 Key strategic moves and developments
10.8 Sartorius AG
10.8.1 Company overview
10.8.2 Company snapshot
10.8.3 Operating business segments
10.8.4 Product portfolio
10.8.5 Business performance
10.8.6 Key strategic moves and developments
10.9 Sysmex Corporation
10.9.1 Company overview
10.9.2 Company snapshot
10.9.3 Operating business segments
10.9.4 Product portfolio
10.9.5 Business performance
10.9.6 Key strategic moves and developments
10.10 Thermo Fisher Scientific Inc.
10.10.1 Company overview
10.10.2 Company snapshot
10.10.3 Operating business segments
10.10.4 Product portfolio
10.10.5 Business performance
10.10.6 Key strategic moves and developments
For more information about this report visit https://www.researchandmarkets.com/r/airj2b
Attachment
Flow Cytometry Market
Shares of Bank of America (NYSE: BAC) were down on Tuesday, falling as much as 6% during the trading day. As of 2:45 p.m. ET, Bank of America was down 5.5%, trading at $32.58. The major indexes were all down on Tuesday, led by the Nasdaq Composite, which was down 258 points, or 2.3%, while the Dow Jones Industrial Average was down 498 points, or 1.5%, and the S&P 500 was off 77 points, or 1.9%, as of 2:45 p.m. ET.
Shares of many of America's largest banks are tumbling again on Tuesday after a period of outperformance that saw Goldman Sachs Group GS claw back practically all of its losses year-to-date.
Should investors prepare for a winter full of persistent headwinds? Inflation remains high, rising interest rates are putting a squeeze on capital as well as making consumer credit more expensive, and both the China COVID lockdowns and the Russian war in Ukraine continue to crimp global supply chains. But even though the markets are facing serious headwinds, not every stock is going to react by falling. According to the analysts at Wall Street giant Deutsche Bank, two interesting stocks are like
General Electric, whose spinoff of its health care and energy companies will leave Evendale-based GE Aerospace as the sole company, bought out every single print add in the New York Times for the first time in the newspaper's history.
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Don’t get fooled into thinking the stock market’s recent positive action has legs. Morgan Stanley’s Chief U.S. Equity Strategist Mike Wilson thinks it’s time to take profits “before the Bear returns in earnest.” Wilson notes that his team’s tactical targets have been met and thinks the recent run-up has run its course. “Bear market rally runs into our original resistance levels–it's time to fade it,” says Wilson. With the “risk-reward of playing for more upside quite poor at this point,” Wilson
Oppenheimer Senior Analyst Christopher Glynn joins Yahoo Finance Live to discuss upgrading GE to Outperform, the company’s stock performance, industrial stocks, and the outlook for GE’s health care spinoff.
Binance CEO CZ is speaking out against SBF after FTX’s collapse and arguing he had nothing to do with his rival’s downfall.
The FTX-linked trading firm made a number of unorthodox investments in the months leading up to its stunning collapse.
The market rally has erased all the gains from Fed chief Jerome Powell's Nov. 30 speech. Apple and Exxon undercut key levels. Here's what to do now.
A strong jobs report these days runs counter to the Fed’s wishes. The line of thought is that if the job market is still too hot, the Fed won’t be keen on loosening its tight monetary policy in the ongoing efforts to tame inflation. And this is a scenario the market is keen to avoid after a series of 75 basis-point hikes this year. But J.P. Morgan Asset Management chief strategist David Kelly thinks the latest numbers flatter to deceive and believes the way the data is reported distorts the real
While NIO and Li Auto (LI) hit monthly-record deliveries in November, XPeng (XPEV) sees a sharp fall in deliveries on a yearly basis.
A broad cross-section of stocks tumbled again on Tuesday as market watchers focused on the Federal Reserve Bank's ongoing battle against inflation. Over the past several days, a couple of strong economic reports have increased concerns about the trajectory of an already overheated economy. With that as a backdrop, shares of Amazon (NASDAQ: AMZN) fell 2%, Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG) tumbled 2.4%, and Shopify (NYSE: SHOP) had slumped 4% as of 12:19 p.m. ET.
Blackstone Inc said redemptions from its $50 billion non-traded business development company reached its pre-set limit for the first time but investors were still allowed to cash out on their investments. This is the first time redemption requests had reached the pre-set limit of 5% since Blackstone launched the product in January last year. It also comes after Blackstone announced last Thursday that it would curb withdrawals from its $69 billion unlisted real estate income trust (REIT) following a surge in redemption requests.
Shares of Devon Energy (NYSE: DVN) fell 11.4% in November, according to data provided by S&P Global Market Intelligence. The primary factor weighing on the oil stock was its third-quarter report, where the company unveiled a lower total dividend payment. Devon Energy launched the oil industry's first fixed-plus-variable dividend framework in early 2021.
Recessions aren't fun to live through. But if you're prepared, they don't have to be painful for your portfolio, either.
DEEP DIVE Stocks of companies that raise dividends consistently have outperformed during this year’s bear market. Below is a screen showing which stocks are analysts’ favorites for next year among an expanded list of Dividend Aristocrats.
The EV stock has been stuck in a range in recent weeks. That isn't going to change for a while, but if it does, the risk is skewed to the downside.
When investors are in "risk-off" mode, unprofitable EV companies are often the first to be sold.
(Bloomberg) — President Joe Biden celebrated Taiwan Semiconductor Manufacturing Co.’s plans to increase its investments in Arizona to $40 billion and construct a second factory, with companies like Apple Inc. eager to source more chips from the US.Most Read from BloombergTrump Companies Are Convicted in NY Criminal Tax Fraud Trial‘Huge, Missing and Growing:’ $65 Trillion in Dollar Debt Sparks ConcernWall Street Goes Risk Off as Bank CEOs Sound Alarm: Markets WrapEx-Deutsche Bank Trader Builds $